Fahad Ullah M. Breast Cancer: Current Perspectives on the Disease Status. Advances in Experimental Medicine and Biology. Volume 1152. Cham: Springer; 2019. pp. 51–64. https://doi.org/10.1007/978-3-030-20301-6_4.

Chapter  Google Scholar 

Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy’. Ann Oncol. 2016;27(8):1482–92. https://doi.org/10.1093/annonc/mdw168.

Article  CAS  PubMed  Google Scholar 

Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186(8):1708–28. https://doi.org/10.1016/J.CELL.2023.01.040.

Article  CAS  PubMed  Google Scholar 

Abbott M, Ustoyev Y. Cancer and the Immune System: The History and Background of Immunotherapy. Semin Oncol Nurs. 2019;35(5). https://doi.org/10.1016/j.soncn.2019.08.002.

Barzaman K, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84. https://doi.org/10.1016/j.intimp.2020.106535.

Leong SP. Immune responses and immunotherapeutic approaches in the treatment against cancer. Clin Exp Metastasis. 2024;41(4):473–93. https://doi.org/10.1007/S10585-024-10300-7

Article  PubMed  PubMed Central  Google Scholar 

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–96. https://doi.org/10.1038/S41573-018-0006-Z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Puntambekar M, Shery N, Parokkaran I, Al-Hamas M. Predictive biomarkers in cancer immunotherapy: a narrative review. Sel Solid Tumors’ Cureus. 2025;17(7). https://doi.org/10.7759/cureus.88647.

Ribeiro R, Carvalho MJ, Goncalves J, Moreira JN. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. Front Mol Biosci. 2022;9(903065). https://doi.org/10.3389/fmolb.2022.903065.

Ciarka A, Piątek M, Pęksa R, Kunc M, Senkus E Tumor-infiltrating lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes. Biomedicines. 2024;12(4):763. https://doi.org/10.3390/biomedicines12040763

Article  CAS  PubMed  PubMed Central  Google Scholar 

‘Definition of pathologic complete response - NCI Dictionary of Cancer Terms - NCI’. Accessed: Apr. 20, 2026. [Online]. Available: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pathologic-complete-response

Di Yu W, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019;452:66–70. https://doi.org/10.1016/j.canlet.2019.02.048.

Article  CAS  PubMed  Google Scholar 

Mina LA, Lim S, Bahadur SW, Firoz AT. Immunotherapy for the Treatment of Breast Cancer: Emerging New Data. Breast Cancer: Targets Therapy. 2020;11:321–8. https://doi.org/10.2147/BCTT.S184710.

Article  Google Scholar 

Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607–17. https://doi.org/10.1007/s00262-020-02736-z.

Article  CAS  PubMed  Google Scholar 

Brown JA, et al. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. J Immunol. 2003;170(3):1257–66. https://doi.org/10.4049/jimmunol.170.3.1257.

Article  CAS  PubMed  Google Scholar 

Leach DR, Krummel MF, Allison JP. Enhancement of Antitumor Immunity by CTLA-4 Blockade’, Science (1979), 271(5256) 1734–1736, 1996. https://doi.org/10.1126/science.271.5256.1734

Article  CAS  Google Scholar 

Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016;44(5):989–1004. https://doi.org/10.1016/j.immuni.2016.05.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cimino-Mathews A, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016;47(1):52–63. https://doi.org/10.1016/J.HUMPATH.2015.09.003.

Article  CAS  PubMed  Google Scholar 

Wimberly H, et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015;3(4):326–32. https://doi.org/10.1158/2326-6066.CIR-14-0133.

Article  CAS  PubMed  Google Scholar 

Liu Q, Cheng R, Kong X, Wang Z, Fang Y, Wang J. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data. Front Immunol. 2020;11:558757. https://doi.org/10.3389/FIMMU.2020.558757/TEXT.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kern R, et al. The Expression of CTLA-4 in Breast Tumors and Tumor-Infiltrating Leukocytes Affects Patients’ Systemic Inflammatory Status and Varies According to Their Molecular Subtypes. Inflammation. 2023;46(5):1639–52. https://doi.org/10.1007/S10753-023-01830-5.

Article  CAS  PubMed  Google Scholar 

Kern R, Panis C CTLA-4 Expression and its clinical significance in breast cancer. Arch Immunol Ther Exp. 2021;69(1):16. https://doi.org/10.1007/S00005-021-00618-5

Article  CAS  Google Scholar 

Yu H, Yang J, Jiao S, Li Y, Zhang W, Wang J. Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. Cancer Immunol Immunother. 2015;64(7):853–60. https://doi.org/10.1007/s00262-015-1696-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Q, et al. Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples. Front Immunol. 2021;12. https://doi.org/10.3389/fimmu.2021.599207.

Fucikova J, et al Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11):1013. https://doi.org/10.1038/s41419-020-03221-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Angelico G, et al. Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist’s Perspective. Cancers (Basel). 2023;15(18):4479. https://doi.org/10.3390/cancers15184479.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu W-D, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019;452:66–70. https://doi.org/10.1016/j.canlet.2019.02.048.

Article  CAS  PubMed  Google Scholar 

Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045–7. https://doi.org/10.1172/JCI9872.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y-L, Chang M-C, Cheng W-F Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett. 2017;400:282–92. . https://doi.org/10.1016/j.canlet.2017.01.040.

Article  CAS  PubMed  Google Scholar 

Biziota E, Mavroeidis L, Hatzimichael E, Pappas P. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Lett. 2017;400:243–51. https://doi.org/10.1016/j.canlet.2016.12.018.

Article  CAS  PubMed  Google Scholar 

Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015;358(2):100–6. https://doi.org/10.1016/j.canlet.2014.12.039.

Article  CAS  PubMed  Google Scholar 

Khan KA, et al. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. NPJ Breast Cancer. 2020;6(1):29. https://doi.org/10.1038/s41523-020-0171-1.

Article  CAS  PubMed  PubMed Central